Bringing the fundamentals into focus…
Back to Theravance Biopharma Inc
How Theravance Biopharma Inc stacks up
TBPH · against 488 other Healthcare companies of similar size
Valuation
63/ 100
Above the middle of the pack.
Ranked #186 of 489 · scores higher than 61% of peers
Bars: peers in each 10-point band of the valuation score37 peers with a valuation score of 60–69, including TBPH · Click a bar to see the companies
Why valuation scores 63?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and free cash flow yield, which are stronger than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 61% of peers. EBITDA yield: 2.1% vs peer median 4.0%
- higher earnings for the price paid: stronger than 84% of peers. Earnings yield: 6.1% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 84% of peers. Free cash flow yield: 6.1% vs peer median 0.0%
Metric by metric
Position: dot = TBPH, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TBPH | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 477 reported | 6.1% | 1.1% | 85% | 30% | |
| EBITDA yieldHigher is better · 495 reported | 2.1% | 4.1% | 40% | 50% | |
| Free cash flow yieldHigher is better · 211 reported | 6.1% | -2.7% | 86% | 20% | |
| Book yieldHigher is better · 485 reported | 32.8% | 41.9% | 37% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around TBPHScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score